Associated tags: Biotechnology, Stevanato Group, Engineering, Health, Pharmaceutical, NYSE, Webcast, Pharmaceutical industry, Medical Supplies, Conference, Science, PIN, Manufacturing
Locations: EUROPE, UNITED STATES, ITALY, NORTH AMERICA, NEW YORK, CT, NEW YORK CITY, CHICAGO
Biotechnology,
Health,
Science,
Pharmaceutical,
Research,
Employment,
COVID-19,
Stevanato Group,
Growth,
Executive,
Multimedia,
Management Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024.
Key Points:
- Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024.
- View the full release here: https://www.businesswire.com/news/home/20240528385017/en/
Franco Stevanato, Chief Executive Officer of Stevanato Group (Photo: Business Wire)
Franco Stevanato commented, “On behalf of the Board of Directors and the Company, I would like to express my sincere gratitude to Mr. Moro for his valuable contributions to Stevanato Group.
- Fabrizio Bonnani, Stevanato Group’s lead independent director, commented, “We thank Franco Moro for his dedicated service to the Company as Chief Executive Officer.
- He embodies the core principles and values of Stevanato Group, and the Board is confident that Franco Stevanato is well positioned to advance the Company’s strategic imperatives and drive long-term shareholder value.”
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on May 22, 2024, have passed.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on May 22, 2024, have passed.
- Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company’s corporate website at https://ir.stevanatogroup.com/ .
- Further information regarding the AGM is available on the investors’ section of Stevanato Group’s corporate website at https://ir.stevanatogroup.com/ , including the full text of the AGM notice, explanatory report and other AGM materials.
- Shareholders may request a hard copy of AGM materials, free of charge, by emailing [email protected] .
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences.
- The Company will present at the William Blair Growth Stock Conference in Chicago on Tuesday, June 4, 2024 at 4:00 p.m. (CT), and at the Jefferies Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:30 a.m.(ET).
- A live webcast of each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section.
- Replays of the webcasts will be available for approximately 90 days after each event.
Health,
Science,
Pharmaceutical,
Research,
Health Technology,
Glass,
Syringe,
PIN,
Conference call,
Depreciation,
Maruti Suzuki,
Conference,
Webcast,
Stevanato Group,
Growth,
Public expenditure,
EPS,
Biopharmaceutical,
Government,
Biotechnology,
Engineering Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2024.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2024.
- For the first quarter of 2024, revenue decreased 1% (40 basis points on a constant currency basis) to €236.0 million, compared with the same period last year.
- Lower revenue from EZ-fill® vials unfavorably impacted the mix within high-value solutions in the first quarter of 2024.
- Conference call: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss financial results.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024.
- The Company will present on Wednesday, May 15, 2024 at 11:20 a.m. (PT).
- A live webcast will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section.
- A replay of the webcast will be available for approximately 90 days after the event.
Health,
Other Science,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Conference call,
Webcast,
HD,
Conference,
PIN Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).
- Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss financial results.
- During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.
- Webcast: A live, listen-only webcast of the call will be available at the following link: STVN webcast .
Medical Supplies,
Medical Devices,
Health,
Other Health,
Pharmaceutical,
Biotechnology,
Organization,
DiaSorin,
Growth,
Stevanato Group,
Information,
Piombino Dese,
Ugo,
Investment,
Multimedia,
Development,
Management Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
- View the full release here: https://www.businesswire.com/news/home/20240404727049/en/
Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire)
The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain.
- Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations.
- “I am honored to help lead Stevanato Group's journey towards operational excellence, driving sustainable growth across our global footprint while fostering innovation," said Ugo Gay, Chief Operations Officer at Stevanato Group.
Medical Supplies,
Health,
Medical Devices,
Other Health,
General Health,
Pharmaceutical,
Biotechnology,
Citigroup,
BofA Securities,
Exercise,
Offering,
Form,
Telephone,
Stevanato Group,
William Blair & Company,
Sale,
Attention,
Security (finance),
Prospectus,
Morgan Stanley,
KeyBank,
Varick Street,
2nd Floor Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
Key Points:
- Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
- The total gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $379.7 million, or approximately $189.8 million from each of the Company Offering and the Selling Shareholder Offering.
- Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.
- Morgan Stanley and William Blair served as lead book-running managers and as representatives of the underwriters for the Offering.
Medical Supplies,
Health,
Medical Devices,
Other Health,
General Health,
Pharmaceutical,
Biotechnology,
Citigroup,
BofA Securities,
Exercise,
Offering,
Form,
Telephone,
Stevanato Group,
William Blair & Company,
Sale,
Attention,
Security (finance),
Prospectus,
Morgan Stanley,
KeyBank,
Varick Street,
2nd Floor Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.
- Stevanato Group is offering 6,350,000 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), which currently holds approximately 78% of Stevanato Group’s outstanding ordinary shares, is offering 6,350,000 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
- Stevanato Group and the Selling Shareholder have granted the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase up to 1,905,000 additional ordinary shares on the same terms and conditions.
- Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.
Retrieved on:
Wednesday, March 20, 2024
Medical Supplies,
Health,
Medical Devices,
Research,
Science,
Pharmaceutical,
Biotechnology,
Form,
Telephone,
Stevanato Group,
William Blair & Company,
Sale,
Attention,
Security (finance),
Prospectus,
Morgan Stanley,
Varick Street,
2nd Floor Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.
- Stevanato Group is offering $150,000,000 of its ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), which currently holds approximately 78% of Stevanato Group’s outstanding ordinary shares, is offering $150,000,000 of its ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
- Stevanato Group and the Selling Shareholder also intend to grant the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase additional ordinary shares up to an amount equal to 15% of the aggregate number of ordinary shares offered in the Offering on the same terms and conditions.
- Stevanato Group intends to use the net proceeds from the Company Offering for general corporate purposes, including to enable Stevanato Group to satisfy the requirements of its ongoing investment activities and working capital needs, and to ensure an appropriate level of operating and strategic flexibility.
